Neurophysiology Unit, Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.
Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Chiang Mai, 50200, Thailand.
Eur J Nutr. 2022 Aug;61(5):2493-2505. doi: 10.1007/s00394-022-02839-6. Epub 2022 Feb 23.
Our previous studies demonstrated the beneficial effects of the probiotic Lactobacillus paracasei HII01, prebiotic xylooligosaccharide (XOS), and synbiotics on several parameters in high-fat diet (HFD)-induced obese rats. However, the gut microbiota composition in these rats has not been investigated. Therefore, this study aimed to investigate the impact of biotic therapies on gut microbiota in HFD-induced obese-insulin-resistant rats.
Male Wistar rats were fed with a normal diet (ND, n = 5) and a HFD (n = 20) for 24 weeks. At week 13, HFD-fed rats were given either a probiotic (L. paracasei, HF-Pro, n = 5), prebiotic (XOS, HF-Pre, n = 5), synbiotic (XOS + L. paracasei, HF-Syn, n = 5), or vehicle (HF-V, n = 5) for 12 weeks. ND-fed rats received vehicle (ND-V, n = 5). At week 24, all rats were decapitated, and metabolic parameters and gut microbiota were analyzed.
HF-V rats developed an obese-insulin-resistant condition as indicated by impaired metabolic parameters. The prebiotic and synbiotic restored those metabolic parameters to the same level of ND-V rats. The gut microbiota composition of ND-V and HF-V rats differed as indicated by beta diversity. Verrucomicrobia in ND-V rats and Firmicutes and Proteobacteria in HF-V rats were dominant. Interestingly, Verrucomicrobia was also prominent in the HF-Syn rats. HF-Pre rats showed a distinct gut microbiota the predominant family being Ruminococcaceae.
The changes in gut microbiota after HFD consumption included increased Firmicutes and Proteobacteria. The treatment with the prebiotic and synbiotic showed an association with the increase in Ruminococcaceae and Verrucomicrobia, respectively. These changes in gut microbiota due to biotics may mediate the beneficial effects on metabolic parameters.
我们之前的研究表明，益生菌副干酪乳杆菌 HII01、益生元木低聚糖（XOS）和合生剂对高脂肪饮食（HFD）诱导肥胖大鼠的几个参数都有有益的影响。然而，这些大鼠的肠道微生物群组成尚未得到研究。因此，本研究旨在探讨生物治疗对 HFD 诱导肥胖-胰岛素抵抗大鼠肠道微生物群的影响。
雄性 Wistar 大鼠分别喂食正常饮食（ND，n=5）和高脂肪饮食（HFD，n=20）24 周。在第 13 周，HFD 喂养的大鼠分别给予益生菌（副干酪乳杆菌，HF-Pro，n=5）、益生元（XOS，HF-Pre，n=5）、合生剂（XOS+副干酪乳杆菌，HF-Syn，n=5）或载体（HF-V，n=5）治疗 12 周。ND 喂养的大鼠给予载体（ND-V，n=5）。第 24 周，所有大鼠断头处死，分析代谢参数和肠道微生物群。
HF-V 大鼠出现代谢参数受损的肥胖-胰岛素抵抗状态。益生元和合生剂将这些代谢参数恢复到 ND-V 大鼠的水平。ND-V 和 HF-V 大鼠的肠道微生物群组成不同，表明β多样性存在差异。ND-V 大鼠以韦荣球菌科为主，HF-V 大鼠以厚壁菌门和变形菌门为主。有趣的是，HF-Syn 大鼠中也存在丰富的韦荣球菌科。HF-Pre 大鼠的肠道微生物群以瘤胃球菌科为主。
HFD 摄入后肠道微生物群的变化包括厚壁菌门和变形菌门的增加。益生元和合生剂的治疗分别与瘤胃球菌科和韦荣球菌科的增加相关。这些由于生物制剂引起的肠道微生物群的变化可能介导了对代谢参数的有益影响。
